1. Why timelines matter
The single most common reason peptide protocols fail isn't the wrong compound — it's abandoning a working protocol before it has time to work. Peptides are not acute drugs. Most require weeks of consistent dosing before measurable outcomes accumulate.
Understanding realistic timelines also prevents the opposite error: continuing a protocol past the point where it's producing benefit, assuming that longer means better.
💡 Tip: Set a minimum 8-week commitment before evaluating a protocol. Track quantitative metrics (pain scores, body weight, sleep quality rating, or whatever is relevant to your goal) from day 1. Subjective memory is unreliable over weeks.
2. Healing & recovery peptides (BPC-157, TB-500)
| Timeframe | What typically happens |
|---|---|
| Days 1–7 | Anti-inflammatory effects may begin. Some researchers notice reduced soreness or swelling within the first week. Don't read too much into early subjective changes. |
| Weeks 2–4 | Pain scores often start improving noticeably. Sleep quality related to injury discomfort may improve. Mobility can begin returning. |
| Weeks 4–8 | Structural repair is ongoing. Most researchers report the majority of improvement occurring in this window for soft-tissue injuries. |
| Weeks 8–12 | Ongoing improvement. Chronic injuries may continue responding. Some researchers run 12-week protocols for severe or longstanding injuries. |
| After stopping | Healing effects persist — the repair done is real. There is no rebound deterioration when you stop. |
Note: These timelines assume a legitimate injury or inflammatory condition being targeted. BPC-157 and TB-500 are not cosmetic or performance compounds — results are proportional to the need for healing.
3. GH-axis peptides (CJC-1295, ipamorelin, sermorelin)
| Timeframe | What typically happens |
|---|---|
| Week 1–2 | Improved sleep quality (especially deep sleep) is often the first noticeable effect — GH pulses primarily occur during slow-wave sleep. |
| Weeks 2–4 | Improved recovery between training sessions. Some notice skin quality changes. Mild water retention is common initially. |
| Weeks 4–8 | Body composition changes begin. Fat loss and muscle retention become measurable with consistent tracking. Energy levels typically improve. |
| Weeks 8–12 | Most body composition benefit accrues here with consistent training and nutrition. IGF-1 levels (if tested) should be measurably elevated. |
| Beyond 12 weeks | Diminishing returns. Receptor desensitisation can occur with some GHRPs at continuous high doses. Cycling off for 4–8 weeks is recommended. |
⚠️ Important: GH-axis results are highly sensitive to sleep quality, training load, and caloric status. Running a GH secretagogue while sleeping poorly and eating in a large surplus will not produce the same outcomes as the same compound with optimised sleep and appropriate nutrition.
4. Fat loss peptides (AOD-9604, semaglutide analogues, tirzepatide)
| Timeframe | What typically happens |
|---|---|
| Week 1–2 | GLP-1 agonists: appetite suppression begins, often dramatically. Nausea is common in the first 1–2 weeks. AOD-9604: limited early effects. |
| Weeks 2–6 | GLP-1 agonists: consistent caloric deficit from appetite suppression drives weight loss. 0.5–1 kg/week is realistic. |
| Weeks 6–12 | Continued fat loss. GLP-1 agonists typically plateau as the body adapts — dose escalation may be required if still within safe range. |
| After stopping | GLP-1 agonists: weight regain is common and well-documented. These compounds manage appetite while present; they don't permanently reset setpoints. |
5. Cognitive peptides (Semax, Selank, PE-22-28)
| Timeframe | What typically happens |
|---|---|
| Day 1–3 | Semax: many researchers report acute cognitive clarity within the first few doses. Some notice improved focus same day. |
| Week 1–2 | Anxiolytic effects (Selank): often apparent within the first week. Mood stabilisation, reduced cortisol response to stressors. |
| Weeks 2–6 | BDNF-mediated effects (Semax, PE-22-28): neuroprotective and cognitive-enhancing effects build over time with consistent use. |
| After stopping | Effects are typically not permanent — they require ongoing dosing for maintenance. Some researchers cycle on/off to preserve responsiveness. |
6. What disrupts timelines
- Inconsistent dosing. Skipping doses — especially for compounds that work by maintaining sustained signalling — extends the timeline or prevents it from working at all. Set a daily alarm.
- Poor sleep. Most healing and GH-axis peptides work through or alongside sleep physiology. Poor sleep quality is one of the biggest protocol killers.
- Continuing to injure the area (for healing peptides). BPC-157 doesn't make you bulletproof — training through acute pain while on a healing protocol delays recovery.
- No tracking. Without baseline measurements and consistent logging, it's easy to misremember where you started and incorrectly conclude something isn't working.
- Underdosing. Starting at the bottom of the dose range is correct — but if you're seeing nothing at 4 weeks, moving up within the documented range is appropriate before concluding the compound doesn't work for you.